Nurix Therapeutics Fiscal Q3 Swings to Profit, Revenue Rises; Shares Gain After Hours

04:23 PM EDT, 10/12/2026 (MT Newswires) -- Nurix Therapeutics (NRIX) reported fiscal Q3 net income late Monday of $4.73 per diluted share, swinging from the loss of $1.03 a year earlier. Analysts polled by FactSet expected a loss $0.60. Collaboration revenue in the three months ended Aug. 31 rose to $19.9 million from $7.89 million a year earlier. Analysts expected $21.5 million. The company reported license revenue of $653.2 million. Nurix shares rose 6.1% in after-hours trading.